Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine for Epiphora and Ptosis
NCT03266081Phase 2Withdrawn
- Sponsor
- McMaster University
- Start
- Apr 2015
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bupivacaine in epiphora and ptosis, sponsored by McMaster University. Primary endpoint: Change from Baseline Lacrimal Tear Lake at 6 months. Planned start Apr 2015; status: withdrawn.
02
Drugs
bupivacaine
03
Conditions
epiphoraptosis
Beyond the preview
Go deeper on NCT03266081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03266081.